Liver Transplantation With ADV-TK Gene Therapy Improves Survival in Patients With Advanced Hepatocellular Carcinoma
The overall survival in the LT with ADV-TK gene therapy group was 54.8 % at three years, and
the recurrence-free survival in the same group was 56.5 %, both being higher than those in
the transplantation only group (P=0.0001 for overall survival and P=0.0000 for
recurrence-free survival). In no-vascular invasion subgroup treated with LT with ADV-TK
therapy, both overall survival and recurrence-free survival were 100 %, significantly higher
than those with vascular invasion subgroup treated with the combined LT and ADV-TK therapy
(P=0 for each group). Vascular invasion was an important factor affected survival and
recurrence, hazard ratio=3.687; P=0.014 and hazard ratio=12.961; P=0.000, respectively.
Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
overall survival rate at one year
Ding Ma, M.D.
Cancer Biology Research Center, Tongji Hospital, Tongji Medical college, Huazhong University of Science and Technology, Wuhan, Hubei 430030, P.R.China
China: Ministry of Health